Role of obinutuzumab exposure on clinical outcome of follicular lymphoma treated with first‐line immunochemotherapy

AIMS: Obinutuzumab (G) is a humanized type II, Fc‐glycoengineered anti‐CD20 monoclonal antibody used in various indications, including patients with previously untreated front‐line follicular lymphoma. We investigated sources of variability in G exposure and association of progression‐free survival...

Descripción completa

Detalles Bibliográficos
Autores principales: Jamois, Candice, Gibiansky, Ekaterina, Gibiansky, Leonid, Buchheit, Vincent, Sahin, Denis, Cartron, Guillaume, Marcus, Robert, Hiddemann, Wolfgang, Seymour, John F., Strefford, Jonathan C., Hargreaves, Chantal E., Meneses‐Lorente, Georgina, Frey, Nicolas, Fingerle‐Rowson, Günter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6595360/
https://www.ncbi.nlm.nih.gov/pubmed/30866056
http://dx.doi.org/10.1111/bcp.13920

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6595360/
https://www.ncbi.nlm.nih.gov/pubmed/30866056
http://dx.doi.org/10.1111/bcp.13920

Ejemplares similares